Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors

Tinelli, Andrea; Malzoni, Mario; Cosentino, Francesco; Perone, Ciro; Tinelli, Andrea; Malvasi, Antonio; Cicinelli, Ettore

doi:10.1016/j.fertnstert.2008.07.1716

Cited by 40 publications

(21 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both patients had FIGO stage I disease and no recurrence was diagnosed after 4 year follow-up. Several studies have demonstrated that laparoscopic surgery is safe and effective for the staging and management of borderline ovarian tumors in young women with early stage diseases who wish to preserve their fertility [12][13][14]. Our technique allows practical conversion to conservative laparoscopy when borderline ovarian tumor is found intra-operatively.…”

Section: Discussionmentioning

confidence: 95%

Leak-proof extracorporeal drainage for management of large ovarian tumors

Weng

Wang

2011

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Leak-proof extracorporeal drainage for management of large ovarian tumors

Weng

Wang

2011

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

“…If BOT is apparently in the early stages, it is necessary to perform a comprehensive staging. This can be achieved through continuing to perform laparoscopy by gynaecologist oncologists or by converting the surgery to laparotomy (37,38). The evidence overall suggests that laparoscopy as a primary approach in BOT is effective and safe (34, 38).…”

Section: Role Of Laparoscopy In Bot Surgerymentioning

confidence: 99%

Diagnosis and Management of Borderline Ovarian Tumor Based on the Iranian Guidelines

Akhavan¹,

Mousavi²,

Alibakhshi³

2016

Obstet Gynecol Cancer Res

View full text Add to dashboard Cite

Borderline ovarian tumors (BOT) consist of epithelial ovarian lesions that express cytological features of malignancy, but unlike malignant ovarian tumors, do not show obvious stromal invasion. The tumor incidence is between 1.8 and 4.8 per 100,000 females per year. The two major groups of BOT include serous BOT (S-BOT) and mucinous BOT (M-BOT). S-BOTs are divided into two categories: tumors limited to ovary and tumors spreading outside the ovary. M-BOTs are divided into two categories. The more common type is intestinal that constitutes 85% of cases and the second type is endocervical or Mullerian. Mullerian M-BOTs is bilateral in 40% of cases, while it is accompanied by pelvic endometriosis in 20-30% of patients. Microscopic examination by intraoperative frozen section is necessary because macroscopic view of ovarian tumors alone is not reliable. It is better to perform conservative surgery until the final report is ready in patients who wish to preserve their fertility. It is hard to differentiate them based on clinical characteristics. Values of tumor markers including CA125, CA19-9 and CEA in diagnosis of BOT are confirmed. Standard treatment of BOT is surgery as is the case with invasive epithelial ovarian cancer. In the majority of patients referred for BOT, since there is no suspicion of malignancy, staging is not performed. In these cases, making decision to repeat surgery and staging depend on factors such as the type of histology, abdominal exploration results in the previous surgery and probability of the presence of residual tumor.

show abstract

“…This is especially true for such rare coincidences as BOT and family planning. However, with the average age at diagnosis being lower than in epithelial ovarian cancer (EOC), the question of fertility preserving therapy is of special importance [8]. In order to evaluate the treatment standard for BOT in Germany, the ROBOT study of the AGO-Ovar (Arbeitsgemeinschaft Gynäkologische Onkologie-Ovar) was initiated.…”

Section: Introductionmentioning

confidence: 99%